Home > Insider Trading > Filing (0001062993-23-006327)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1478320	Adaptive Biotechnologies Corp	ADPT	Biological Products, (No Disgnostic Substances) (2836)	270907024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808905	Mark R Adams	C/O Adaptive Biotechnologies Corporation 1165 Eastlake Avenue East Seattle WA 98109	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-06	88,652	$0.00	202,170	No	4	A	Direct
Common Stock	Disposition	2023-03-06	6,529	$8.57	195,641	No	4	S	Direct
Common Stock	Disposition	2023-03-07	17,155	$8.60	178,486	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-03-06	133,033	$0.00	133,033	$8.46

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
133,033		2033-03-06	No	4	A	Direct

Footnotes

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.245 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.